OBR Daily Commentary

forumImage

Phase III Trial of Anticancer Agent Lenvima As First-Line Treatment For Unresectable Hepatocellular Carcinoma Meets Primary Endpoint

(Eisai) Jan 25, 2017 - Eisai Co., Ltd. announced today that a Phase III clinical trial (Study 304) of its in-house discovered and developed anticancer agent Lenvima® (lenvatinib mesylate, “lenvatinib”) against the comparator sorafenib as a first-line treatment for patients with unresectable hepatocellular carcinoma has achieved its primary endpoint.

Read Article arrow

Dean Gesme, MD (Posted: January 25, 2017)

quotesA very welcome advance in HCC therapy with lenvatinib dosing which is lower than the initial recommended dosing for radioiodine-resistant well differentiated thyroid cancers. Much greater expense may be an important issue compared to sorafenib. Also the second line role of regorafenib may need some further consideration versus using sorafenib in the second line.quotes

Add Comment 1 Comment
forumImage

'Ton of Bricks' Dropped on Popular Cancer Gene Panels?

(Medscape Medical News) Dec 28, 2016 - The results from two widely used genetic sequencing tests can differ "markedly" in the same patient, according to investigators who compared the FoundationOne (F1; Foundation Medicine) and Guardant360 (G360; Guardant Health) tests.

Read Article arrow

Dean Gesme, MD (Posted: January 04, 2017)

quotesProviders have a responsibility to fully understand the serious limitations of the tests which we are constantly being enticed to order based on theoretical promises of "patient benefit". We must see through the smoke and mirrors in order to fully comprehend the true state of new developments in order to justify the tests we do and then to correctly inform our treatment recommendations based on those tests.quotes

Add Comment 1 Comment
forumImage

Next Big Thing in ER+ Breast Cancer: For Early-Stage Too?

(Medscape Medical News) Dec 8, 2016 - Two agents that inhibit cyclin-dependent kinases 4 and 6 (CDK4/6) have yielded unprecedented results in progression-free survival in clinical trials involving postmenopausal women with estrogen-receptor (ER) positive, HER2-negative metastatic breast cancer.

Read Article arrow

Dean Gesme, MD (Posted: December 10, 2016)

quotesIt is encouraging to see three competing CDK 4/6 inhibitors soon to be available. With the huge potential market consisting of ER + great cancer, it will be a great case study in market pricing --- I.e. competitive capitalism vs collaborative market maintainance.quotes

Add Comment 1 Comment

Meet the Editorial Board

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Associate Cancer Center Director, Yale Cancer Center P...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...